Akıllı Fatih Mehmet, Turan-Gökçe Dilara, Akıllı Beste
Microbiology Laboratory, Sincan Training and Research Hospital, Ankara, Türkiye.
Department of Gastroenterology, Sincan Training and Research Hospital, Ankara, Türkiye.
Infect Dis Clin Microbiol. 2025 Mar 27;7(1):27-36. doi: 10.36519/idcm.2025.447. eCollection 2025 Mar.
Hepatitis C virus (HCV) infection represents a significant public health concern. In order to contribute to the epidemiological data, the present investigation aimed to examine the prevalence of antibodies against the virus, viremia, incidence rates of co-infections with the human immunodeficiency virus (HIV), and the genotypes (GTs) of HCV among patients in the capital city of Turkey.
This study was conducted retrospectively at Sincan Training and Research Hospital between January 1, 2021 and December 31, 2023. The patients' demographic data were obtained from the hospital database. The samples of patients were analyzed for the presence of anti-HCV by using Architect anti-HCV kit (Abbott Laboratories, USA) and MAGLUMI HIV Ab/AgCombi (SNIBE, Shenzen, China), and for the presence of HCV-RNA (QIAsymphony). They were also analyzed using the SP/AS method (Qiagen, Germany) with the QIAsymphony DSP virus/pathogen midi kit, and the polymerase chain reaction was performed by using the Rotor-Gene-Q (Qiagen, Germany) and Artus HCV QS-RGQ kit. Genotyping for HCV was conducted on all patients with detectable viral load. To confirm the presence of HIV in patients with viremia, a supplemental assay for HIV-1/2 (Bio-Rad, USA) was employed. Additionally, the HCV/HIV co-infection rate was calculated.
A total of 63,226 patient samples were analyzed. Of the 522 patients who were found to be anti-HCV positive, 267 were patients admitted from prison. Anti-HCV prevalence among inmates in 2021, 2022, and 2023 was 3.8%, 4.2%, and 2.7%, respectively. The study revealed a prevalence of 0.8% for HCV antibody positivity and a viremia prevalence of 0.4%. Among 239 patients, HCV GT3 (27.9%) was found to be the most common GT, and this was followed by GT1 (26.2%), GT2 (7%), and GT4 (4.1%). Genotyping revealed that subtype 1b was present in 36.5% of GT1 patients, and subtype 1a was present in 33.3%. HCV/HIV co-infection rates were detected as 4.1%.
Our study will contribute to the elimination programs of HCV, an important public health problem, and the epidemiological data in our region.
丙型肝炎病毒（HCV）感染是一个重大的公共卫生问题。为了补充流行病学数据，本调查旨在检测土耳其首都患者中抗该病毒抗体的流行率、病毒血症、人类免疫缺陷病毒（HIV）合并感染率以及HCV的基因型（GTs）。
本研究于2021年1月1日至2023年12月31日在辛坎培训与研究医院进行回顾性研究。患者的人口统计学数据从医院数据库中获取。使用Architect抗-HCV试剂盒（美国雅培实验室）和MAGLUMI HIV Ab/AgCombi（中国深圳新产业生物医学工程股份有限公司）分析患者样本中抗-HCV的存在情况，并使用QIAsymphony检测HCV-RNA。还使用德国Qiagen公司的QIAsymphony DSP病毒/病原体 midi试剂盒采用SP/AS方法进行分析，并使用德国Qiagen公司的Rotor-Gene-Q和Artus HCV QS-RGQ试剂盒进行聚合酶链反应。对所有病毒载量可检测的患者进行HCV基因分型。为确认病毒血症患者中HIV的存在，采用了美国Bio-Rad公司的HIV-1/2补充检测方法。此外，计算了HCV/HIV合并感染率。
共分析了63226份患者样本。在522名抗-HCV呈阳性的患者中，267名是从监狱收治的患者。2021年、2022年和2023年囚犯中的抗-HCV流行率分别为3.8%、4.2%和2.7%。研究显示HCV抗体阳性率为0.8%，病毒血症流行率为0.4%。在239名患者中，HCV GT3（27.9%）是最常见的基因型，其次是GT1（26.2%）、GT2（7%）和GT4（4.1%）。基因分型显示，GT1患者中1b亚型占36.5%，1a亚型占33.3%。检测到的HCV/HIV合并感染率为4.1%。
我们的研究将有助于消除HCV这一重要的公共卫生问题以及我们地区的流行病学数据。
